# Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)

> **NCT01452750** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 642 (actual)

## Conditions studied

- Gastric Ulcers
- Duodenal Ulcers

## Interventions

- **DRUG:** TAK-438
- **DRUG:** Placebo
- **DRUG:** TAK-438
- **DRUG:** Placebo
- **DRUG:** Lansoprazole
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01452750
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 642 (ACTUAL)
- **Last updated:** 2014-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01452750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01452750, "Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01452750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*